Through analysis of the Exome Aggregation Consortium cohort, excluding The Cancer Genome Atlas (TCGA), ATM germline PVs are prevalent in approximately 0.44% of the population, and higher rates are present in certain types of cancer patients [10]. This evidence concerns the gene ATM and cancer.